Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rong Sun

Showing results (1121-1130 of 1,124) with videos related to

Pageof 113
Sort By:
You have reached the last page of results.This site can display upto 1,124 results.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Cancer Cell|November 16, 2004
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2Jonathan Oliner, Hosung Min, Juan Leal, et al.
Pageof 113

Showing results (1121-1130 of 1,124) with videos related to

Sort By:
Pageof 113
You have reached the last page of results.This site can display upto 1,124 results.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Cancer Cell|November 16, 2004
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2Jonathan Oliner, Hosung Min, Juan Leal, et al.
Pageof 113